Literature DB >> 18037526

Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy.

Sébastien Deshayes1, May Morris, Frédéric Heitz, Gilles Divita.   

Abstract

The recent discovery of new potent therapeutic molecules which do not reach the clinic due to poor delivery and low bioavailability have made of delivery a key stone in therapeutic development. Several technologies have been designed to improve cellular uptake of therapeutic molecules, including cell-penetrating peptides (CPPs), which have been successfully applied for in vivo delivery of biomolecules and constitute very promising tools. Distinct families of CPPs have been described; some require chemical linkage between the drug and the carrier for cellular drug internalization while others like Pep-and MPG-families, form stable complexes with drugs depending on their chemical nature. Pep and MPG are short amphipathic peptides, which form stable nanoparticles with proteins and nucleic acids respectively. MPG and Pep based nanoparticles enter cells independently of the endosomal pathway and efficiently deliver cargoes in a fully biologically active form into a large variety of cell lines as well as in animal models. This review will focus on the mechanisms of non-covalent MPG and Pep-1 strategies and their applications in cultured cells and animal models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037526     DOI: 10.1016/j.addr.2007.09.005

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  43 in total

Review 1.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

2.  Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide.

Authors:  Anke Detzer; Marita Overhoff; Winfried Wünsche; Maria Rompf; John J Turner; Gabriela D Ivanova; Michael J Gait; Georg Sczakiel
Journal:  RNA       Date:  2009-02-18       Impact factor: 4.942

3.  Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery.

Authors:  Kathryn A Whitehead; Gaurav Sahay; George Z Li; Kevin T Love; Christopher A Alabi; Minglin Ma; Christopher Zurenko; William Querbes; Robert S Langer; Daniel G Anderson
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

4.  Delivery of macromolecules into live cells by simple co-incubation with a peptide.

Authors:  Ya-Jung Lee; Alfredo Erazo-Oliveras; Jean-Philippe Pellois
Journal:  Chembiochem       Date:  2010-02-15       Impact factor: 3.164

Review 5.  Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment.

Authors:  James C Cummings; Haiwen Zhang; Andrew Jakymiw
Journal:  Transl Res       Date:  2019-07-29       Impact factor: 7.012

6.  Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems.

Authors:  Eisaku Kondo; Ken Saito; Yuichi Tashiro; Kaeko Kamide; Shusei Uno; Tomoko Furuya; Masao Mashita; Kiichiro Nakajima; Tomoyuki Tsumuraya; Naoya Kobayashi; Masahiro Nishibori; Mitsune Tanimoto; Masayuki Matsushita
Journal:  Nat Commun       Date:  2012-07-17       Impact factor: 14.919

7.  Tumor-targeted RNA-interference: functional non-viral nanovectors.

Authors:  Xinghua Pan; Rachel Thompson; Xiaojie Meng; Daocheng Wu; Liang Xu
Journal:  Am J Cancer Res       Date:  2011-09-01       Impact factor: 6.166

8.  Functional Delivery of siRNA by Disulfide-Constrained Cyclic Amphipathic Peptides.

Authors:  Jade J Welch; Ria J Swanekamp; Christiaan King; David A Dean; Bradley L Nilsson
Journal:  ACS Med Chem Lett       Date:  2016-03-30       Impact factor: 4.345

9.  Development of Guanidinium-Rich Protein Mimics for Efficient siRNA Delivery into Human T Cells.

Authors:  Brittany M deRonde; Joe A Torres; Lisa M Minter; Gregory N Tew
Journal:  Biomacromolecules       Date:  2015-09-14       Impact factor: 6.988

Review 10.  Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.

Authors:  S D Laufer; T Restle
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.